Identification of novel substrates for human cytochrome P450 2J2

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 347-356

  Lee, Caroline A ^a   Neul, David ^a   Clouser Roche, Andrea ^a   Dalvie, Deepak ^a   Wester, Michael R ^a   Jiang, Ying ^a   Jones III, J P ^b   Freiwald, Sascha ^a   Zientek, Michael ^a   Totah, Rheem A ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ACETAZOLAMIDE; ALBENDAZOLE; AMANTADINE; AMILORIDE; AMIODARONE; AMITRIPTYLINE; AMODIAQUINE; AMOXICILLIN; AMPHOTERICIN; ASTEMIZOLE; ATENOLOL; AZATHIOPRINE; AZITHROMYCIN; BENAZEPRIL; BEPRIDIL; BISOPROLOL; CYCLOSPORIN; CYTOCHROME P450 2J2; CYTOCHROME P450 3A4; DANAZOL; EBASTINE; MESORIDAZINE; METHOTREXATE; NABUMETONE; PHENAZONE; TAMOXIFEN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG;

ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MICROSOME; PRIORITY JOURNAL;

ALGORITHMS; CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; INTESTINES; ISOENZYMES; KINETICS; LIVER; MICROSOMES; MODELS, STRUCTURAL; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 76149089080     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030270     Document Type: Article

References (33)

1. Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, and LLerena A (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59:45-50.
2. Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, and de Waziers I (2007) Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742.
3. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, and Thummel KE (2004) In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68:1889-1902.
4. Dehal SS and Kupfer D (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402-3406.
5. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen C, Zeldin DC, and Goldstein JA (2007) Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688.
6. Eap CB, Guentert TW, Schãublin-Loidl M, Stabl M, Koeb L, Powell K, and Baumann P (1996) Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 59:322-331.
7. Fabre G, Julian B, Saint-Aubert B, Joyeux H, and Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
8. Hashizume T, Imaoka S, Mise M, Terauchi Y, Fujii T, Miyazaki H, Kamataki T, and Funae Y (2002) Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298-304.
9. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
10. Johnson EF and Stout CD (2005) Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338:331-336.
11. Jones JP, Katayama JH, Jiang Y, Lee CA, and Totah RA (2008) Identification of danazol as a selective inhibitor of cytochrome P450 2J2 (Abstract). Drug Metab Rev 40:78.
12. Kronbach T, Fischer V, and Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630-635.
13. Lafite P, Dijols S, Buisson D, Macherey AC, Zeldin DC, Dansette PM, and Mansuy D (2006) Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett 16:2777-2780.
14. Lafite P, Francois A, Zeldin DC, Dansette PM, and Mansuy D (2007) Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 46:10237-10246.
15. Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, Oh SJ, Yun CH, and Shin JG (2005) Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 15:105-113.
16. Li W, Tang Y, Liu H, Cheng J, Zhu W, and Jiang H (2008) Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking. Proteins 71:938-949.
17. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, and Shou M (2001) Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368-374.
18. Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH, Choi CS, Choi YK, Desta Z, and Shin JG (2006) Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793-1797.
19. Matsumoto S, Hirama T, Kim HJ, Nagata K, and Yamazoe Y (2003) In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica 33:615-623.
20. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240-1245.
21. Matsumoto S and Yamazoe Y (2001) Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol 51:133-142.
22. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, and Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303-1310.
23. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
24. Rawden HC, Kokwaro GO, Ward SA, and Edwards G (2000) Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49:313-322.
25. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
26. Rosi D, Neumann HC, Christiansen RG, Schane HP, and Potts GO (1977) Isolation, synthesis, and biological activity of five metabolites of danazol. J Med Chem 20:349-352.
27. Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779-815.
28. Salih IS, Thanacoody RH, McKay GA, and Thomas SH (2007) Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 82:548-554.
29. Sridar C, Kent UM, Notley LM, Gillam EM, and Hollenberg PF (2002) Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 301:945-952.
30. Stäubli M, Bircher J, Galeazzi RL, Remund H, and Studer H (1983) Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol 24:485-494.
31. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, and Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49:234-240.
32. Wójcikowski J, Maurel P, and Daniel WA (2006) Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 34:471-476.
33. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.